…
CVS Health Corporation provides health solutions in the United States. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPS and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, medical spend management services, pharmacy and other administrative services. It serves employers, insurance companies, unions, government employee groups, health plans, PDPS, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, personal care products, and other general merchandise products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
CVS Health operates an integrated healthcare platform combining retail pharmacy, pharmacy-benefit management (Caremark) and health insurance through Aetna, while expanding outpatient care services. Long-term growth may come from aging-driven prescription demand, PBM and retail scale, Medicare Advantage expansion and efficiencies from vertical integration. These features may appeal due to diversified recurring revenues and scope to improve margins through care coordination and cost control.
Key risks include regulatory pressure on drug pricing and PBMs, government reimbursement exposure, competitive disruption from retailers and digital entrants, and execution or leverage risk from acquisitions.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 2136.00M | 6148.00M | 11173.00M | 5628.00M | 10420.00M |
| Minority interest | 40.00M | 28.00M | -24.00M | 16.00M | -12.00M |
| Net income | 1768.00M | 4614.00M | 8344.00M | 4311.00M | 7910.00M |
| Selling general administrative | 970.00M | 40240.00M | 38360.00M | 745.00M | 36934.00M |
| Selling and marketing expenses | - | 989.00M | 985.00M | - | - |
| Gross profit | 55362.00M | 51401.00M | 54431.00M | 54294.00M | 52048.00M |
| Reconciled depreciation | 4606.00M | 4597.00M | 4366.00M | 4247.00M | 4512.00M |
| Ebit | 5255.00M | 9086.00M | 13743.00M | 16251.00M | 13193.00M |
| Ebitda | 9861.00M | 13683.00M | 13743.00M | 20498.00M | 19676.00M |
| Depreciation and amortization | 4606.00M | 4597.00M | 4366.00M | 4247.00M | 6483.00M |
| Non operating income net other | - | - | - | 169.00M | -270.00M |
| Operating income | 10385.00M | 8516.00M | 13743.00M | 16251.00M | 13193.00M |
| Other operating expenses | 391682.00M | 364293.00M | 600963.00M | 306385.00M | 277129.00M |
| Interest expense | 3119.00M | 2958.00M | 2658.00M | 2287.00M | 2503.00M |
| Tax provision | 408.00M | 1562.00M | 2805.00M | 1463.00M | 2522.00M |
| Interest income | 3119.00M | 2958.00M | 2658.00M | 2287.00M | 2503.00M |
| Net interest income | -3119.00M | -2958.00M | -2658.00M | -2287.00M | -2503.00M |
| Extraordinary items | - | - | - | 0.00M | 0.00M |
| Non recurring | - | - | - | 8336.00M | 431.00M |
| Income tax expense | 408.00M | 1562.00M | 2805.00M | 1463.00M | 2522.00M |
| Total revenue | 402067.00M | 372809.00M | 357776.00M | 322467.00M | 292111.00M |
| Total operating expenses | 44977.00M | 42885.00M | 39832.00M | 38212.00M | 37066.00M |
| Cost of revenue | 346705.00M | 321408.00M | 303345.00M | 268173.00M | 240063.00M |
| Total other income expense net | -8249.00M | -2368.00M | -2570.00M | -10623.00M | -2773.00M |
| Net income from continuing ops | 1728.00M | 4586.00M | 8368.00M | 4165.00M | 7898.00M |
| Net income applicable to common shares | 1768.00M | 4614.00M | 8344.00M | 4149.00M | 7910.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 261064.00M | 253215.00M | 249728.00M | 228275.00M | 232999.00M |
| Intangible assets | 25508.00M | 27323.00M | 29234.00M | 24754.00M | 29026.00M |
| Other current assets | 5032.00M | 3076.00M | 3151.00M | 2685.00M | 5292.00M |
| Total liab | 185682.00M | 177485.00M | 173092.00M | 156960.00M | 157618.00M |
| Total stockholder equity | 75214.00M | 75560.00M | 76461.00M | 71015.00M | 75075.00M |
| Deferred long term liab | - | - | - | 3880.00M | 6270.00M |
| Other current liab | 23441.00M | 61223.00M | 59579.00M | 47562.00M | 5604.00M |
| Common stock | 18.00M | 18.00M | 48992.00M | 48193.00M | 47377.00M |
| Capital stock | 50402.00M | 49661.00M | 48992.00M | 48193.00M | 47377.00M |
| Retained earnings | 61196.00M | 62837.00M | 61604.00M | 56145.00M | 54906.00M |
| Other liab | - | - | - | 19948.00M | 19663.00M |
| Good will | 85478.00M | 91272.00M | 91272.00M | 78150.00M | 79121.00M |
| Other assets | 7113.00M | 8104.00M | 7910.00M | 7604.00M | 9801.00M |
| Cash | 8512.00M | 8586.00M | 8196.00M | 12945.00M | 9408.00M |
| Cash and equivalents | 8453.00M | 8586.00M | 8196.00M | 12945.00M | 9408.00M |
| Total current liabilities | 88692.00M | 84609.00M | 79189.00M | 69736.00M | 67807.00M |
| Current deferred revenue | 62.00M | - | 57112.00M | 3880.00M | 43808.00M |
| Net debt | 85081.00M | 74334.00M | 71189.00M | 57787.00M | 66591.00M |
| Short term debt | 5805.00M | 7494.00M | 4713.00M | 3456.00M | 5851.00M |
| Short long term debt | 4068.00M | 5743.00M | 2972.00M | 1778.00M | 4205.00M |
| Short long term debt total | 93593.00M | 82920.00M | 79385.00M | 70732.00M | 75999.00M |
| Other stockholder equity | 13594.00M | 12825.00M | -33838.00M | -31858.00M | -28173.00M |
| Property plant equipment | 28056.00M | 28937.00M | 30435.00M | 12873.00M | 12896.00M |
| Total current assets | 74714.00M | 68645.00M | 67858.00M | 65682.00M | 60008.00M |
| Long term investments | 32669.00M | 28934.00M | 23019.00M | 21096.00M | 23025.00M |
| Net tangible assets | - | - | - | 71015.00M | -33072.00M |
| Short term investments | 2145.00M | 2407.00M | 3259.00M | 2778.00M | 3117.00M |
| Net receivables | 39779.00M | 36469.00M | 35227.00M | 27276.00M | 24431.00M |
| Long term debt | 60502.00M | 60527.00M | 58638.00M | 50476.00M | 51971.00M |
| Inventory | 19246.00M | 18107.00M | 18025.00M | 19090.00M | 17760.00M |
| Accounts payable | 59384.00M | 15892.00M | 14897.00M | 14838.00M | 12544.00M |
| Noncontrolling interest in consolidated entity | - | - | - | 300.00M | 306.00M |
| Accumulated other comprehensive income | 406.00M | -120.00M | -297.00M | -1465.00M | 965.00M |
| Common stock total equity | - | - | - | 48193.00M | 47377.00M |
| Retained earnings total equity | - | - | - | 56145.00M | 54906.00M |
| Treasury stock | - | - | - | -31858.00M | -28173.00M |
| Non currrent assets other | 6913.00M | 8104.00M | 7910.00M | 3968.00M | 4714.00M |
| Non current assets total | 186350.00M | 184570.00M | 181870.00M | 162593.00M | 172991.00M |
| Capital lease obligations | 15380.00M | 16650.00M | 17775.00M | 18478.00M | 19823.00M |
| Long term debt total | 60502.00M | 60527.00M | 58638.00M | 50476.00M | 51971.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -2629.00M | -7613.00M | -19766.00M | -1017.00M | -2717.00M |
| Change to liabilities | - | - | - | 4260.00M | 5919.00M |
| Total cashflows from investing activities | -5871.00M | -7613.00M | -20889.00M | -5047.00M | -5261.00M |
| Net borrowings | -1779.00M | 5059.00M | 7932.00M | -4211.00M | -9267.00M |
| Total cash from financing activities | -4940.00M | -1135.00M | 2683.00M | -10516.00M | -11356.00M |
| Change to operating activities | - | - | - | 7149.00M | 3018.00M |
| Net income | 1768.00M | 4586.00M | 8368.00M | 4165.00M | 7898.00M |
| Change in cash | -172.00M | 359.00M | -4780.00M | 614.00M | 1648.00M |
| Begin period cash flow | 8884.00M | 8525.00M | 13305.00M | 12691.00M | 11043.00M |
| End period cash flow | 8712.00M | 8884.00M | 8525.00M | 13305.00M | 12691.00M |
| Total cash from operating activities | 10639.00M | 9107.00M | 13426.00M | 16177.00M | 18265.00M |
| Depreciation | 4606.00M | 4597.00M | 4366.00M | 4247.00M | 4512.00M |
| Other cashflows from investing activities | 26.00M | 101.00M | 68.00M | -1303.00M | -24.00M |
| Dividends paid | 3397.00M | 3373.00M | 3132.00M | 2907.00M | 2625.00M |
| Change to inventory | -1267.00M | -102.00M | 1233.00M | -1435.00M | 735.00M |
| Change to account receivables | -3498.00M | -1301.00M | -6260.00M | -2971.00M | -2703.00M |
| Sale purchase of stock | 394.00M | -3023.00M | -2012.00M | -3500.00M | 549.00M |
| Other cashflows from financing activities | 1961.00M | 202.00M | -105.00M | -449.00M | 1523.00M |
| Change to netincome | - | - | - | 2533.00M | 549.00M |
| Capital expenditures | 2832.00M | 2781.00M | 3031.00M | 2727.00M | 2520.00M |
| Change receivables | - | - | - | 2971.00M | -2703.00M |
| Cash flows other operating | - | - | - | 16177.00M | 1355.00M |
| Cash and cash equivalents changes | - | - | - | 614.00M | 1648.00M |
| Change in working capital | -1474.00M | 109.00M | 15.00M | 7003.00M | 3948.00M |
| Stock based compensation | 535.00M | 540.00M | 588.00M | 447.00M | 484.00M |
| Other non cash items | 10345.00M | -153.00M | 765.00M | 2390.00M | 1851.00M |
| Free cash flow | 7807.00M | 6326.00M | 10395.00M | 13450.00M | 15745.00M |
Sector: Healthcare Industry: Healthcare Plans
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CVS CVS Health Corp |
-11.14 12.19% |
80.27 | 55.65 | 10.80 | 0.25 | 1.32 | 0.42 | 17.09 |
| UNH UnitedHealth Group Incorporated |
4.94 1.22% |
409.38 | 22.57 | 18.38 | 1.33 | 5.65 | 1.38 | 13.97 |
| ELV Elevance Health Inc |
- -% |
434.18 | 18.47 | 14.58 | 0.45 | 2.05 | 0.56 | - |
| CI Cigna Corp |
9.97 3.37% |
305.41 | 11.94 | 8.68 | 0.27 | 1.80 | 0.36 | 7.93 |
| HUM Humana Inc |
-0.45 0.11% |
417.42 | 38.47 | 26.45 | 0.33 | 2.54 | 0.39 | - |
CVS Health Corporation provides health solutions in the United States. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPS and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, medical spend management services, pharmacy and other administrative services. It serves employers, insurance companies, unions, government employee groups, health plans, PDPS, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, personal care products, and other general merchandise products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.
| Name | Title | Year Born |
|---|---|---|
| Ms. Karen Sue Lynch | Pres, CEO & Director | 1963 |
| Mr. Shawn Michael Guertin | Exec. VP & CFO | 1964 |
| Dr. Alan M. Lotvin M.D. | Exec. VP & Pres of Pharmacy Services | 1962 |
| Mr. James David Clark | Sr. VP, Controller & Chief Accounting Officer | 1965 |
| Mr. Tilak Mandadi | Exec. VP & Chief Data, Digital and Technology Officer | 1964 |
| Mr. Larry McGrath | Sr. VP of Bus. Devel. & Investor Relations | NA |
| Mr. Thomas Michael Moriarty | Exec. VP, Chief Policy & External Affairs Officer and Gen. Counsel | 1964 |
| Mr. David A. Falkowski | Exec. VP & Chief Compliance Officer | NA |
| Mr. Norman de Greve | Chief Marketing Officer | NA |
| Ms. Laurie P. Havanec | Exec. VP & Chief People Officer | 1961 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.